The Canonsburg-based company reported net income of $2.6 million, or a penny per share, for the three months ended Dec. 31, down from $4.1 million, or a penny per share, a year ago. The most recent quarter included an additional 67.5 million shares of common stock outstanding.

Revenue rose 6 percent to $1.43 billion from $1.35 billion.

Excluding charges, including purchase accounting items and litigation expenses, the company said it earned 45 cents per share. Analysts polled by FactSet expected adjusted earnings per share of 45 cents and revenue of about $1.46 billion.

Operating expenses rose 6 percent to $485 million while interest expense rose 17 percent to $91.5 million.

For the full year, the company had net income of $223.5 million, or 68 cents per share, compared with $93.5 million, or 30 cents per share, in 2009. Revenue rose to $5.45 billion from $5.09 billion.

Looking ahead, the company expects 2011 profit between $1.90 and $2.10 per share on revenue between $6.1 billion and $6.4 billion. Analysts expect profit of about $1.99 per share on revenue of about $6.05 billion.

Generic drug maker Mylan Inc. said Thursday that its fourth-quarter profit fell 38 percent on higher costs and charges, but adjusted results meet Wall Street expectations.

Copyright ©2026— Trib Total Media, LLC (TribLIVE.com)